The label does not forbid it: neither the Zepbound nor the Wegovy label lists alcohol as an interaction [1] [2]. What the tirzepatide label does list overlaps with drinking. Nausea hit up to 29% of people on the drug, against 8% on placebo, and vomiting hit up to 13%, against 2%. In type 2 diabetes with a sulfonylurea, low blood sugar was reported in 10.3%.
What the label says, and what it leaves out
Tirzepatide’s label lists two drug interactions, and alcohol is neither of them. The first is insulin or an insulin secretagogue, such as a sulfonylurea. The second is oral medication, because the drug slows gastric emptying [1].
The word alcohol appears in the label only as an ingredient, benzyl alcohol, in the pen and the vial. The same silence holds for semaglutide’s Wegovy label [2], so a person asking whether they can drink on semaglutide gets the same first answer.
That silence is a fact about the label, and it is not a clearance. Three warnings the label does carry sit close to a night of drinking, and each is set out below with its number.
Stomach effects and fluid loss
The stomach effects are the common ones. In the label’s weight-loss trials, nausea ran at 25%, 29% and 28% across the 5 mg, 10 mg and 15 mg arms, against 8% on placebo. Diarrhea ran at 19% to 23%, and vomiting at 8% to 13% [1].
Those fluid losses carry a separate warning. The label reports acute kidney injury after marketing, in some cases requiring dialysis. Most reported events followed nausea, vomiting or diarrhea that led to dehydration. The label tells patients to take precautions against fluid depletion, especially while starting or raising the dose [1].
The label does not say what alcohol adds to this, so the practical reading is narrow. It singles out the weeks of starting or raising the dose as the ones to watch. Longer-term kidney data point the other way, as set out in the kidney outcome trials. That finding covers years on the drug, not a dehydrated week.
Low blood sugar, which depends on what else you take
On its own, tirzepatide rarely drives blood sugar low enough to matter. In adults without type 2 diabetes, a reading under 54 mg/dL was reported in 0.3%, against none on placebo. The label notes that trial did not capture lows systematically [1].
The figure changes with diabetes medication. In people with type 2 diabetes, lows ran at 4.2% on the drug against 1.3% on placebo. With a sulfonylurea on board the rate was 10.3%, and without one it was 2.1% [1].
The label’s fix is a lower dose of the insulin or sulfonylurea, and it says nothing about drinking on top of that combination. Anyone on either drug should put the alcohol question to whoever manages the insulin. The mechanism, and why the drug alone rarely causes it, is in the low blood sugar guide.
Pancreatitis, where alcohol is its own cause
The label warns of acute pancreatitis, including fatal cases, across the drug class. In the two weight-loss trials, confirmed pancreatitis ran at 0.2% on tirzepatide and 0.2% on placebo [1]. The label’s instruction is to stop the drug if pancreatitis is suspected.
Alcohol and gallstones are both causes a doctor rules out first. One UK hospital reviewed 222 pancreatitis admissions over a year, and four patients, or 1.8%, were on tirzepatide. All four cases were mild, with no intensive care admission. Two had gallstones, one reported alcohol intake, and one had no other cause found [6].
Four cases cannot settle causation, and the audit says so. The pooled trial picture is in the side effects guide, where pancreatitis came back null. The gallstone route, which rapid weight loss can open, is covered in the gallbladder guide. The symptom to act on is the same either way: the label names persistent or severe abdominal pain, sometimes running to the back.
Does a drink feel different on tirzepatide?
One small study measured it. Twenty people with obesity drank a set dose of alcohol, and half of them were taking a GLP-1 drug. Breath alcohol and the felt effects both rose later in the GLP-1 group, and nausea did not explain the delay [4].
That study measured timing; it did not report a lower peak, or measure impairment. The authors read the delay as a possible reason people drink less on these drugs. It is a pilot, and they call the evidence preliminary.
Do people drink less on it?
Some users report doing so, on self-reported data. A remote study recruited 153 current drinkers with a BMI of 30 or more. People taking semaglutide or tirzepatide for at least 30 days reported lower intake and fewer binge episodes. That held against their own past and against a control group [3].
A larger health-record study looked at new diagnoses instead of intake. In 7,165 matched people with type 2 diabetes, tirzepatide was linked to fewer new alcohol use disorder diagnoses over 18 months. The hazard ratio was 0.47 against DPP-4 inhibitors, which is an association, not a trial [5].
None of the 35 PubMed records pairing tirzepatide with alcohol is a randomized human trial, as of September 18, 2026. The trial evidence on drinking belongs to semaglutide, and it is mixed. The oral semaglutide trial in alcohol use disorder missed its primary endpoint. That is a treatment question, and a separate one from whether a drink is safe.
What this page does not cover
Every figure above is for brand tirzepatide, at the doses on its label. A compounded preparation is not FDA-approved, and the FDA does not review it before it is dispensed. The warnings above describe the molecule, not a given vial. The questions to ask about a compounded product are in the compounded safety guide.